Azilsartan medoxomil
- Generic Name
- Azilsartan medoxomil
- Brand Names
- Edarbyclor, Edarbi
- Drug Type
- Small Molecule
- Chemical Formula
- C30H24N4O8
- CAS Number
- 863031-21-4
- Unique Ingredient Identifier
- LL0G25K7I2
- Background
Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend...
- Indication
Azilsartan medoxomil is indicated for the treatment of hypertension to lower blood pressure in patients over 18 years of age. It may be used either alone or in combination with other antihypertensive agents. Some antihypertensive drugs have lesser effects on blood pressure in black patients.
...
- Associated Conditions
- Albuminuria, Hypertension, Atrial Fibrillation
- Associated Therapies
- -
Azilsartan in Patients With Diabetic Kidney Disease and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 106
- Registration Number
- NCT05753696
- Locations
- 🇨🇳
the Second Afficiated Hospital, Zhejiang University, School of Medicine, Hanzhou, Zhejiang, China
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 341
- Registration Number
- NCT04606563
- Locations
- 🇨🇦
Royal Jubilee Hospital, Nanaimo, British Columbia, Canada
🇨🇦St Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Celltrion Pharm, Inc.
- Target Recruit Count
- 3438
- Registration Number
- NCT04470817
- Locations
- 🇰🇷
Myongji Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT02791438
International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1945
- Registration Number
- NCT02756819
- Locations
- 🇰🇿
Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan
🇰🇿Kazakh Medical University of Continuing Education, Almaty, Kazakhstan
🇷🇺Medical center Lotos, Chelyabinsk, Russian Federation
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
- Conditions
- Interventions
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 380
- Registration Number
- NCT02517866
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 612
- Registration Number
- NCT02480764
- Locations
- 🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Beijing Anzhen Hospital, Beijing, Beijing, China
A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2016-04-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 6
- Registration Number
- NCT02451150
Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 304
- Registration Number
- NCT02407210
- Locations
- 🇨🇳
Beijing ANZHEN Hospital, Beijing, China
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Takeda
- Registration Number
- NCT02400775
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.